Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis
Gaia Ninatti, Pietro Scilipoti, Cristiano Pini, Francesco Barletta, Mattia Longoni, Fabrizia Gelardi, Martina Sollini, Giorgio Gandaglia, Mike Sathekge, Francesco Montorsi, Arturo Chiti, Alberto Briganti
Abstract
PSMA-TAT holds promising efficacy and an acceptable safety profile for treating metastatic prostate cancer. Randomised controlled trials are needed to optimise treatment protocols toward the implementation of PSMA-TAT into clinical practice.
Topics & Concepts
Prostate cancerMedicineMeta-analysisOncologyCancer researchCancerAlpha (finance)Internal medicineSurgeryPatient satisfactionConstruct validityProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis